{
    "organizations": [],
    "uuid": "50afa556fd6f126abb78f960074308d737cb7ff3",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/01/23/pr-newswire-regeneron-to-report-fourth-quarter-and-full-year-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on.html",
    "ord_in_thread": 0,
    "title": "Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "TARRYTOWN, N.Y., Jan. 23, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2017 financial and operating results on Thursday, February 8, 2018, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.\nConference Call Information\nTo access this call, dial (800) 708-4539 (U.S.) or (847) 619-6396 (International). A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com . A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.\nAbout Regeneron\nRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, Regeneron's unique ability to consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates, all of which were homegrown in its laboratories. Regeneron's medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.\nRegeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite ® technologies, including VelocImmune ® to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.\nFor additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.\nContact Information:\nInvestor Relations\nCorporate Communications\nManisha Narasimhan, Ph.D.\nHala Mirza\n914.847.5126\n914.847.3422\nmanisha.narasimhan@regeneron.com\nhala.mirza@regeneron.com\nView original content: http://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-8-2018-300586890.html\nSOURCE Regeneron Pharmaceuticals, Inc.",
    "published": "2018-01-24T00:05:00.000+02:00",
    "crawled": "2018-01-24T00:57:40.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "tarrytown",
        "regeneron",
        "pharmaceutical",
        "nasdaq",
        "regn",
        "today",
        "announced",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "operating",
        "result",
        "thursday",
        "february",
        "financial",
        "market",
        "open",
        "company",
        "host",
        "conference",
        "call",
        "simultaneous",
        "webcast",
        "eastern",
        "time",
        "day",
        "conference",
        "call",
        "information",
        "access",
        "call",
        "dial",
        "international",
        "link",
        "webcast",
        "may",
        "accessed",
        "presentation",
        "page",
        "regeneron",
        "website",
        "replay",
        "conference",
        "call",
        "webcast",
        "archived",
        "company",
        "website",
        "available",
        "day",
        "regeneron",
        "regeneron",
        "nasdaq",
        "regn",
        "leading",
        "biotechnology",
        "company",
        "invents",
        "medicine",
        "people",
        "serious",
        "disease",
        "founded",
        "led",
        "year",
        "regeneron",
        "unique",
        "ability",
        "consistently",
        "translate",
        "science",
        "medicine",
        "led",
        "six",
        "treatment",
        "numerous",
        "product",
        "candidate",
        "homegrown",
        "laboratory",
        "regeneron",
        "medicine",
        "pipeline",
        "designed",
        "help",
        "patient",
        "eye",
        "disease",
        "heart",
        "disease",
        "allergic",
        "inflammatory",
        "disease",
        "pain",
        "cancer",
        "infectious",
        "disease",
        "rare",
        "disease",
        "regeneron",
        "accelerating",
        "improving",
        "traditional",
        "drug",
        "development",
        "process",
        "proprietary",
        "velocisuite",
        "technology",
        "including",
        "velocimmune",
        "yield",
        "optimized",
        "antibody",
        "ambitious",
        "initiative",
        "regeneron",
        "genetics",
        "center",
        "one",
        "largest",
        "genetics",
        "sequencing",
        "effort",
        "world",
        "additional",
        "information",
        "company",
        "please",
        "visit",
        "follow",
        "regeneron",
        "twitter",
        "contact",
        "information",
        "investor",
        "relation",
        "corporate",
        "communication",
        "manisha",
        "narasimhan",
        "hala",
        "mirza",
        "view",
        "original",
        "content",
        "http",
        "source",
        "regeneron",
        "pharmaceutical",
        "inc"
    ]
}